Medication Adherence Gap — Non-adherence is the problem this market was built to solve. Roughly half of people with asthma don't take controller medicine as prescribed, and a systematic review of connected inhaler trials found that electronic monitoring with reminders raises adherence compared with usual care. The cost shows up downstream: a CDC-led analysis published in 2018 put the annual U.S. cost of asthma at US$81.9 Bn in medical care, missed work and deaths. Asthma, at 56.0% of 2025 revenue (USD 698.2 Mn), carries most of this demand. Smart inhalers convert each actuation into a time-stamped record, so a clinician can tell whether a worsening patient missed doses or needs a different drug. Adherium put numbers on that in March 2026, reporting that its iCARE program cut hospital costs by 46% and saved U.S. insurers US$12,943 per monitored patient.
Smart Inhalers Market Size, Share, Trends & Forecast 2026–2035
Smart Inhalers Market by Product Type (Add-On Smart Inhalers, Integrated Smart Inhalers, Disposable Smart Inhalers), by Application (Asthma, COPD, Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)), by Connectivity (Bluetooth-Enabled, Cellular-Enabled, NFC-Enabled), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Homecare/Patients, Hospitals & Clinics, Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Smart Inhalers Industry Perspective
The Global Smart Inhalers market was valued at USD 1,246.7 Mn in 2025 and is projected to reach USD 3,934.7 Mn by 2035, growing at a CAGR of 12.18% during the forecast period 2026–2035, according to Vectomat Insights.
North America accounts for 38.0% of 2025 revenue, led by a USD 369.5 Mn U.S. market where new remote patient monitoring billing codes took effect in January 2026, while Asia Pacific posts the fastest regional growth.
Smart Inhalers Market: Overview
Smart Inhalers Market encompasses metered dose and dry powder inhalers with built-in electronics, add-on sensors that attach to conventional inhalers, and single-use connected devices, together with the companion apps that turn actuation data into adherence and technique reports. The report scope covers three product types, three applications (asthma, COPD and other respiratory conditions), Bluetooth, cellular and NFC connectivity, three distribution channels and three end-user settings.
The value chain runs in three tiers. Foundational providers own the drug and the inhaler platform: AstraZeneca, GSK and Chiesi Farmaceutici supply the Aerosphere, Ellipta and Trimbow devices that sensors are cleared against. Specialist developers such as AptarGroup (Aptar Digital Health), Kindeva Drug Delivery and Bespak engineer valves, actuators, propellant systems and connected add-ons. Application-layer specialists, led by Adherium and ResMed's Propeller Health, run the sensor-to-app data platforms that clinicians and payers actually see.
For procurement and investment teams, value is concentrating where reimbursement meets device clearance: Bluetooth add-on sensors for homecare patients in the U.S., and integrated devices timed to the low-carbon propellant switch in Europe. This report tracks that split across 5 segmentation dimensions and 35+ countries, so buyers can size each pocket of demand separately.
According to World Health Organization, Asthma fact sheet, 2024-05, Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019.

Key Insights
- The Global Smart Inhalers market grows from USD 1,246.7 Mn in 2025 to USD 3,934.7 Mn by 2035, a 12.18% CAGR across the 2026–2035 forecast horizon.
- Add-on smart inhalers lead the product mix at 54.0% of 2025 revenue (USD 673.2 Mn), because one clip-on sensor converts an inhaler a patient already uses.
- Integrated smart inhalers are the fastest-growing product type at a 16.17% CAGR, rising from USD 398.9 Mn in 2025 to USD 1,785.8 Mn by 2035.
- Asthma is the dominant application at 56.0% of 2025 revenue (USD 698.2 Mn), reflecting a patient pool the WHO puts at about 262 million people.
- Homecare/Patients is the largest end user at 62.0% share (USD 773.0 Mn), since adherence data matter most between clinic visits.
- North America holds 38.0% of 2025 revenue (USD 473.7 Mn); the U.S. alone is worth USD 369.5 Mn and grows at 11.0% a year.
- Asia Pacific is the fastest-growing region, with South Korea expanding at 14.4% and Japan at 12.5% a year through 2035.
- Competition is split between sensor specialists (Adherium, Aptar) and pharma brand owners (AstraZeneca, GSK, Chiesi); Teva's 2024 Digihaler exit left integrated devices without a large incumbent.
- Bluetooth-enabled devices take 66.0% of 2025 revenue and grow at 14.18% a year, the default link for smartphone-based remote monitoring.

Smart Inhalers Market: Report Scope
| Report Name | Smart Inhalers Market by Product Type (Add-On Smart Inhalers, Integrated Smart Inhalers, Disposable Smart Inhalers), by Application (Asthma, COPD, Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)), by Connectivity (Bluetooth-Enabled, Cellular-Enabled, NFC-Enabled), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Homecare/Patients, Hospitals & Clinics, Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 1,246.7 Mn (2025) |
| Market Forecast in 2035 | USD 3,934.7 Mn (2035) |
| Growth Rate (CAGR) | 12.18% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 118 tables & 86 figures |
| Report Code | VMI-1-2-38666 |
| Report Format | |
| Delivery Format | PDF via email delivery and online download portal |
| Published Date | November 2026 |
| Research Methodology | Primary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation) |
| Key Companies Covered | Adherium, ResMed (Propeller Health), AptarGroup (Aptar Digital Health), Teva Pharmaceutical Industries, AstraZeneca, GSK, Chiesi Farmaceutici, Boehringer Ingelheim, Cipla, Lupin, Kindeva Drug Delivery, Bespak |
| Segments Covered | Product Type, Application, Connectivity, Distribution Channel, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Free customization of up to 10% of report scope, including additional country splits, company profiles or segment cuts |
What Sets This Smart Inhalers Market Report Apart?
Decision-makers comparing market intelligence reports on Smart Inhalers will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 5 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 12 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
Smart Inhalers Market Growth Drivers
New RPM Billing Codes — Payment rules, not technology, set the pace of adoption. Until 2026, U.S. practices could bill the main device-supply code, CPT 99454, only when a patient transmitted at least 16 days of data in a 30-day period, a bar many inhaler users missed. CMS's 2026 Physician Fee Schedule, finalized in November 2025 and effective January 1, 2026, added CPT 99445 for 2 to 15 days of data and CPT 99470 for the first 10 minutes of management time. Adherium said in March 2026 that the lower threshold opens billing for patients who use their inhalers on fewer days. Hospitals & Clinics, the fastest-growing end user at 16.26% a year, are the first to benefit. Structurally, the code change turns a smart inhaler from a one-off device sale into a billable monthly service.
Add-On Sensor Clearances — The supply of cleared sensors is catching up with demand. Aptar Digital Health received FDA 510(k) clearance for its Sense device, a Class II connected add-on for metered dose inhalers, in October 2025, and Poland's FindAir followed with a 510(k) for FindAir ONE in 2026. Adherium's Hailie was already cleared for GSK's Ventolin, Advair, Flovent and Ellipta inhalers and AstraZeneca's Breztri and Airsupra, the widest U.S. drug coverage of any sensor. Each clearance counts because a sensor is tied to specific inhaler geometry, and coverage of the most-prescribed brands decides whether a health system can standardize on one platform. Add-on devices hold 54.0% of 2025 revenue (USD 673.2 Mn) on the strength of this model. Expect the number of cleared drug-device pairs to keep climbing through 2028 as Aptar and newer entrants extend their labels.
The iCARE results show that when patients use Hailie sensors with remote monitoring, adherence to COPD and asthma medicines rises to levels clinicians rarely see in routine care.
Smart Inhalers Market Challenges to Growth
Weak Uptake of Integrated Devices — Clinical promise hasn't guaranteed commercial traction. Teva discontinued its U.S. ProAir, AirDuo and ArmonAir Digihaler range in 2024 and withdrew GoResp Digihaler in the UK after a Class 3 recall in June 2024, and clinician press linked the exits to low prescribing uptake. Integrated devices carry electronics inside each inhaler, so payers face a higher price per fill without guaranteed savings on their own books. The Asthma and Allergy Foundation of America warned that the discontinuation forced another device switch on patients. The result shows in the revenue split: integrated smart inhalers hold 32.0% of 2025 revenue (USD 398.9 Mn), well behind the 54.0% held by add-on sensors.
Data Privacy and Cybersecurity Burden — Every connected inhaler is also a data-security liability. Under section 524B of the U.S. Food, Drug, and Cosmetic Act, sponsors of cyber devices must file cybersecurity plans, software bills of materials and patching processes with their premarket submissions, and legal analysts noted in November 2025 that gaps can create False Claims Act exposure. In Europe, sensors fall under the EU Medical Device Regulation and patient data under GDPR, which multiplies documentation for companies selling on both sides of the Atlantic. Smaller sensor developers feel this most, since compliance costs don't shrink with revenue. Payers add a further hurdle: Germany's GKV-Spitzenverband restated in April 2026 that digital health tools must justify their price against measured patient benefit.
Spending on digital health applications keeps growing, so their quality and their prices have to keep pace with the benefit they actually deliver to patients.
Smart Inhalers Market Growth Opportunities
Low-Carbon Propellant Redesign — Regulation is reopening every MDI design at once. The EU F-gas Regulation (EU) 2024/573 brings inhaler propellants into the hydrofluorocarbon phase-down; the MHRA approved AstraZeneca's Trixeo Aerosphere with near-zero-GWP HFO-1234ze in May 2025, and GSK reported positive Phase III data for an HFA-152a Ventolin in October 2025. Chiesi, Lupin, Kindeva and Bespak are all building capacity for the new propellants. Because each reformulated inhaler must be re-qualified, manufacturers can add sensing and connectivity in the same development cycle instead of paying for a separate redesign later. That is the structural reason integrated smart inhalers are the fastest-growing product type at 16.17% a year.
Outcome-Linked Payer Contracts — Outcome data are turning sensor makers into payer partners. Adherium reported in March 2026 that its iCARE respiratory program cut hospital costs by 46% and saved U.S. insurers US$12,943 per patient, and the company has said it is assessing direct contracts with U.S. payers. Medicare Advantage plans and accountable care organizations carry the cost of COPD readmissions, so they have reason to fund monitoring rather than wait for practices to bill it. COPD holds 36.0% of 2025 revenue and grows at 14.29% a year. Expect the first outcome-linked contracts between sensor vendors and large U.S. health plans before 2028, with COPD programs leading.
Emerging-Market Respiratory Programs — The next large patient pools sit outside the U.S. and Europe. Cipla launched its CipAir asthma screening app in India in January 2025 and expanded its Breathefree respiratory initiative into the UAE in October 2025, building diagnosis channels that connected devices can follow. Saudi Arabia's SEHA Virtual Hospital, which links about 130 hospitals, offers ready infrastructure for remote monitoring. Low-cost Bluetooth and cellular sensors priced for out-of-pocket buyers would suit these markets. Asia Pacific already accounts for 24.0% of 2025 revenue, worth USD 296.6 Mn.
Smart Inhalers Market: Key Challenges
Patient Engagement Drop-Off — Device data are only as good as the patient's willingness to keep the sensor paired. A November 2025 review in EMJ on implementing smart inhalers pointed to fading patient engagement, data overload for clinicians and unclear workflows as practical barriers. In England, NICE's 2025 early-use assessment of digital asthma self-management tools asked for more real-world evidence before routine adoption. Clinicians reviewing paediatric smart inhaler use in Australia raised the same workflow concerns in a 2026 BMJ Open study.
Drug-by-Drug Clearance Burden — A sensor that fits one inhaler doesn't fit the next. Adherium needed separate FDA 510(k) clearances for GSK's Ellipta devices, for Ventolin, Advair and Flovent MDIs, and for AstraZeneca's Airsupra and Breztri, and every new or reformulated inhaler restarts the process. Formulary changes and generic switching can strand a patient's sensor overnight. Structurally, this ties add-on vendors' growth to the release calendars of the pharma companies whose inhalers they serve.
Discontinuing the Digihaler line means people with asthma who relied on it must switch devices, another disruption in care for patients who already face frequent inhaler changes.

AI's Impact on the Smart Inhalers Market
Amiko Digital Health's Respiro platform applies machine learning to the signals a sensor captures during each inhalation to judge whether the technique was right, and a 2025 peer-reviewed study in the International Journal of COPD validated an AI-powered smart dry powder inhaler, the RS01X, built on it. That moves smart inhalers from counting doses to checking how each dose was taken, which matters because poor technique undermines treatment even in adherent patients.
For health systems, AI turns raw actuation logs into risk flags a nurse can act on, which becomes necessary as monitoring caseloads grow under the 2026 CMS codes. Expect exacerbation-risk scoring to become a standard feature of connected inhaler platforms before 2030.
Smart Inhalers Market: Segmentation
The Global Smart Inhalers market is segmented by Product Type, Application, Connectivity, Distribution Channel, End User.
By Product Type
Aptar Digital Health's clip-on sensor for metered dose inhalers won FDA 510(k) clearance in October 2025, and it shows why this format leads. Add-On Smart Inhalers account for 54.0% of 2025 revenue (USD 673.2 Mn): one sensor turns an inhaler the patient already uses into a connected one without a new drug filing, and Adherium's Hailie is cleared for GSK's Ventolin and Ellipta devices and AstraZeneca's Breztri and Airsupra. Integrated Smart Inhalers, at 32.0% (USD 398.9 Mn), are the fastest-growing type, projected to expand at 16.17% a year to USD 1,785.8 Mn by 2035 as low-carbon propellant reformulations open a window to build sensors in at the factory. Disposable Smart Inhalers hold the remaining 14.0% (USD 174.5 Mn) and grow at a slower 5.21%.
Product Type-Wise Revenue Breakdown for the Smart Inhalers Market, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Add-On Smart Inhalers | 525.4 | 571.6 | 673.2 |
| Integrated Smart Inhalers | 307.2 | 351.8 | 398.9 |
| Disposable Smart Inhalers | 160.7 | 161.2 | 174.5 |

By Application
The WHO estimates that asthma affected about 262 million people in 2019, and that patient pool explains the split. Asthma holds 56.0% of 2025 revenue (USD 698.2 Mn), because controller adherence is the clearest use case: a missed daily dose shows up as a gap in the sensor log long before an emergency visit. COPD carries 36.0% (USD 448.8 Mn) and compounds at 14.29% a year as payers target readmissions. The Others category, covering cystic fibrosis, allergic rhinitis and other respiratory conditions, is the fastest-growing application at 19.77%, though from a small 8.0% base (USD 99.7 Mn). AstraZeneca's April 2026 FDA approval of Breztri Aerosphere for asthma, a device Hailie sensors already fit, blurs the line between the two main applications.
Application-Wise Revenue Breakdown for the Smart Inhalers Market, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Asthma | 551.0 | 581.3 | 698.2 |
| COPD | 365.5 | 414.5 | 448.8 |
| Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions) | 76.8 | 88.8 | 99.7 |
By Connectivity
Every leading sensor cleared in the U.S. since 2022, from Adherium's Hailie to Aptar's connected MDI sensor, pairs with a smartphone over Bluetooth Low Energy. Bluetooth-Enabled devices hold 66.0% of 2025 revenue (USD 822.8 Mn) and are also the fastest-growing connectivity type at 14.18% a year, because the patient's own phone does the transmitting and keeps device cost down. Cellular-Enabled devices take 22.0% (USD 274.3 Mn); they serve older patients without smartphones, often through gateways such as Tenovi's, which carries Hailie data into U.S. remote monitoring programs. NFC-Enabled devices, at 12.0% (USD 149.6 Mn), grow at just 3.22%, since tap-to-read syncing leaves gaps between taps that clinicians can't act on.
Connectivity-Wise Revenue Breakdown for the Smart Inhalers Market, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Bluetooth-Enabled | 639.7 | 700.7 | 822.8 |
| Cellular-Enabled | 227.6 | 240.1 | 274.3 |
| NFC-Enabled | 126.0 | 143.8 | 149.6 |
By Distribution Channel
Adherium sells Hailie sensors direct to U.S. consumers under an over-the-counter clearance, an early sign of where volume is heading. Even so, Hospital Pharmacies still lead with 39.6% of 2025 revenue (USD 493.1 Mn), since many programs start at discharge after an exacerbation, when the care team sets up the device. Retail Pharmacies hold 36.4% (USD 454.4 Mn) and are the fastest-growing channel at 16.17% a year, reaching USD 2,035.0 Mn by 2035 as sensors are dispensed alongside the inhaler refill itself. Online Pharmacies account for 24.0% (USD 299.2 Mn) and grow at 5.36%; direct-to-consumer sales build awareness but rarely carry reimbursement.
Distribution Channel-Wise Revenue Breakdown for the Smart Inhalers Market, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Hospital Pharmacies | 388.2 | 441.1 | 493.1 |
| Retail Pharmacies | 334.5 | 369.0 | 454.4 |
| Online Pharmacies | 270.6 | 274.5 | 299.2 |
By End User
Modivcare's October 2024 home monitoring program with Tenovi and Adherium shows where smart inhalers earn their keep: in the patient's home. Homecare/Patients account for 62.0% of 2025 revenue (USD 773.0 Mn), because exacerbations build between appointments and the sensor log is the only record of what happened. Hospitals & Clinics hold 28.0% (USD 349.1 Mn) but are the fastest-growing end user at 16.26% a year, as allergy and pulmonology practices bill remote monitoring under the 2026 CMS codes; Adherium's October 2026 partnership with FLASS in Central Florida is one example. Others, covering long-term care facilities, ambulatory surgical centers and pharmacies, hold 10.0% (USD 124.7 Mn) and grow at 5.29%.
End User-Wise Revenue Breakdown for the Smart Inhalers Market, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Homecare/Patients | 646.5 | 670.3 | 773.0 |
| Hospitals & Clinics | 235.6 | 295.6 | 349.1 |
| Others (Long-term care facilities, ambulatory surgical centers, and pharmacies) | 111.2 | 118.7 | 124.7 |


Smart Inhalers Market: Production & Volume Analysis, 2025
Vectomat Insights estimates about 8.6 million smart inhaler units shipped worldwide in 2025, counting add-on sensors, integrated connected inhalers and single-use connected devices, for an implied average selling price near USD 145 per unit. Add-On Smart Inhalers lead both volume (50.0%, about 4.3 million units) and value. The volume-value split shows up in the other two types: Disposable Smart Inhalers take 28.0% of units but only 14.0% of revenue at roughly USD 72 each, while Integrated Smart Inhalers ship 22.0% of units at about USD 211, the highest unit price in the category.
| Metric | 2025 Volume (units shipped) | Share of Units |
|---|---|---|
| Total units shipped (2025) | 8,600,000 | 100.0% |
| Add-On Smart Inhalers | 4,300,000 | 50.0% |
| Integrated Smart Inhalers | 1,892,000 | 22.0% |
| Disposable Smart Inhalers | 2,408,000 | 28.0% |
Reference point: Adherium — Reported record quarterly remote patient monitoring revenue of A$479K with Hailie device activations nearing its 10,000-unit goal (July 2026).
Smart Inhalers Market: Competitive Landscape
Teva's 2024 withdrawal of its Digihaler range removed the only large integrated smart inhaler portfolio and handed momentum to add-on specialists. Add-on sensors now hold 54.0% of 2025 revenue, and the field is fragmented: no single vendor controls the category, because each sensor is cleared against specific drug-device pairs. Adherium and ResMed's Propeller Health compete for remote monitoring contracts, AptarGroup supplies both valves and its own connected MDI sensor, and AstraZeneca, GSK and Chiesi decide which inhalers get redesigned first. Integrated devices, the fastest-growing product type at 16.17% a year, will favor companies that sit inside the propellant transition. Key players include Adherium, ResMed (Propeller Health), AptarGroup (Aptar Digital Health), Teva Pharmaceutical Industries, AstraZeneca, GSK, Chiesi Farmaceutici, Boehringer Ingelheim, Cipla, Lupin, Kindeva Drug Delivery, and Bespak, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Adherium | Australia | Hailie add-on Bluetooth sensors and remote patient monitoring platform | Sell remote monitoring to U.S. pulmonology and allergy practices and value-based care payers | Partnered with Florida Lung, Asthma & Sleep Specialists (FLASS) in October 2026 to expand Hailie monitoring into Central Florida |
| ResMed (Propeller Health) | United States | Propeller connected inhaler sensors and digital asthma and COPD platform | Concentrate the portfolio on sleep and breathing health under its 2030 strategy | Agreed in July 2026 to sell MatrixCare to Frazier Healthcare Partners for US$490 Mn, sharpening its focus on sleep and connected respiratory care |
| AptarGroup (Aptar Digital Health) | United States | MDI valves and actuators plus the Sense connected add-on for metered dose inhalers | Pair drug-delivery components with connected add-ons and disease-management services for pharma partners | Received FDA 510(k) clearance for its Sense connected add-on for metered dose inhalers, in October 2025 |
| Teva Pharmaceutical Industries | Israel | Branded and generic inhalers, formerly the Digihaler integrated range | Refocus on its branded respiratory pipeline under the Pivot to Growth strategy after exiting Digihaler | Reported a third consecutive year of growth in its full-year 2025 results in January 2026 |
| AstraZeneca | United Kingdom | Aerosphere pressurized MDIs, including Breztri/Trixeo and Airsupra | Move its inhaler range to the near-zero GWP HFO-1234ze propellant while widening labels | Won FDA approval of Breztri Aerosphere for the maintenance treatment of asthma in April 2026 |
| GSK | United Kingdom | Ellipta dry powder inhalers and the Ventolin MDI | Switch Ventolin to a low-carbon HFA-152a propellant with no change to the patient experience | Reported positive pivotal Phase III data for its low-carbon Ventolin MDI in October 2025 |
| Chiesi Farmaceutici | Italy | Trimbow and Fostair pressurized MDIs | Carbon Minimal Inhaler transition backed by a digital respiratory platform built with Aptar | Expanded its partnership with Bespak in March 2026 to produce Carbon Minimal Inhalers at Holmes Chapel, UK |
| Boehringer Ingelheim | Germany | Respimat soft mist inhaler for COPD and asthma | Widen direct patient access and pair devices with digital adherence partners | Launched a U.S. direct-to-consumer platform to expand patient access to its treatments in September 2025 |
| Cipla | India | Breath-actuated and conventional inhalers, the Breathefree program and digital screening | Build diagnosis and adherence programs in India and other emerging markets | Expanded its Breathefree respiratory initiative across the UAE in October 2025 |
| Lupin | India | Generic and branded MDIs for the U.S. and India | Develop low-GWP pressurized MDIs for regulated markets | Agreed with Honeywell in May 2025 to use Solstice Air (HFO-1234ze) propellant in its MDIs |
| Kindeva Drug Delivery | United States | Contract development and manufacturing of pressurized MDIs and DPIs | Convert pharma clients' inhalers to low-GWP propellants | Took the first ISO-tank delivery of Orbia's Zephex 152a low-GWP propellant in October 2025 |
| Bespak | United Kingdom | Pressurized MDI manufacturing at King's Lynn and Holmes Chapel | Specialize in the low-GWP pMDI transition after separating from Recipharm | Agreed in March 2026 to add Holmes Chapel capacity for Chiesi's Carbon Minimal Inhalers |
Three strategic themes run through the competitive set. First, low-carbon propellant programs at AstraZeneca, GSK, Chiesi and Lupin are forcing device re-qualification, the natural moment to embed sensors. Second, sensor vendors are moving from device sales to recurring monitoring revenue billed under the 2026 CMS codes. Third, contract manufacturers such as Kindeva and Bespak are adding capacity for new propellants, which will decide how fast integrated devices reach volume.

Smart Inhalers Market: Value Chain Overview
Propellants, Valves and Components — Upstream suppliers provide the propellants, metering valves, actuators and electronics that every smart inhaler depends on. The low-GWP transition has reset this tier: Honeywell supplies HFO-1234ze and Orbia supplies HFA-152a, while AptarGroup makes valves and its own Sense connected add-on. Qualification cycles are long, so a component chosen for a reformulated inhaler tends to stay in the bill of materials for a decade. Key Players: Orbia delivered its first ISO tank of Zephex 152a to Kindeva in October 2025.
Device Manufacturing and Drug Filling — Pharma brand owners and contract manufacturers fill, assemble and release the inhalers, then seek approval for each drug-device combination. AstraZeneca, GSK and Chiesi run this stage for their own brands, while Kindeva Drug Delivery and Bespak take on capacity for partners. Integrated smart inhalers add electronics assembly and software validation at this step, which raises unit cost and lengthens approval timelines compared with add-on sensors. Key Players: Bespak expanded Holmes Chapel capacity for Chiesi's Carbon Minimal Inhalers in March 2026.
Connected Platforms, Dispensing and Monitoring — The downstream stage turns devices into data. Platform companies such as Adherium and ResMed's Propeller Health supply the apps and clinician dashboards, cellular gateway providers such as Tenovi carry readings for patients without smartphones, and pharmacies and practices dispense the devices and bill monitoring time. Most of the recurring revenue in this market is captured here, which is why sensor makers increasingly sell monitoring services rather than hardware alone. Key Players: Adherium partnered with FLASS in Central Florida in October 2026.
Smart Inhalers Market: Regional Analysis
North America leads with 38.0% of 2025 revenue because U.S. payers now reimburse remote monitoring, while Asia Pacific grows fastest as South Korea and Japan build regulatory and payment routes for connected devices.
North America Smart Inhalers Market
Aptar Digital Health's October 2025 FDA clearance for its connected MDI sensor and FindAir's 2026 clearance for FindAir ONE added two more add-on sensors to a U.S. market that already had Adherium's Hailie. North America holds 38.0% of 2025 revenue (USD 473.7 Mn), and the U.S. alone is worth USD 369.5 Mn, growing at 11.0% a year to about USD 1,049.2 Mn by 2035. Reimbursement drives the region: CMS's 2026 Physician Fee Schedule added CPT 99445 and 99470, so practices can bill monitoring with only 2 to 15 days of data a month. The weak spot is the integrated segment, where Teva's 2024 withdrawal of its ProAir, AirDuo and ArmonAir Digihaler line left prescribers wary of switching patients to a connected device again.
The U.S. Smart Inhalers Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 369.5 Mn |
| Forecast Value (2035) | USD 1,049.2 Mn |
| CAGR (2026–2035) | 11% |

Europe Smart Inhalers Market
The UK's MHRA approved AstraZeneca's Trixeo Aerosphere with a near-zero global warming potential propellant in May 2025, the first inhaled medicine of its kind, and that regulatory push shapes Europe's market. Europe holds 26.0% of 2025 revenue (USD 324.1 Mn). Germany leads at USD 94.0 Mn and expands at 10.6% a year to about USD 257.4 Mn by 2035, while NICE's 2025 early-use assessment of digital asthma self-management tools gives England an evidence pathway that most of the continent lacks. Payment is the sticking point: Germany's statutory insurers have pushed back on the price of digital health applications relative to proven benefit. Structurally, European demand is tied to the EU F-gas phase-down, because every inhaler reformulated for a new propellant has to be re-qualified as a device.
Germany Smart Inhalers Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 94.0 Mn |
| Forecast Value (2035) | USD 257.4 Mn |
| CAGR (2026–2035) | 10.6% |

Asia Pacific Smart Inhalers Market
South Korea's Digital Medical Products Act took effect in January 2025, giving connected devices their own regulatory track, and it is one reason Asia Pacific is the fastest-growing region in this market. Asia Pacific holds 24.0% of 2025 revenue (USD 296.6 Mn). South Korea, worth USD 59.8 Mn, is the region's fastest-growing country at 14.4% a year and reaches about USD 229.6 Mn by 2035; Japan is larger at USD 83.8 Mn and grows at 12.5%. India adds scale, with Cipla launching its CipAir asthma screening app in January 2025 for an estimated 34 million Indian asthma patients. The challenge is price sensitivity outside Japan, Korea and Australia, where patients pay out of pocket. Expect the region's share to climb steadily through 2035 as payment for connected devices spreads.
South Korea Smart Inhalers Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 59.8 Mn |
| Forecast Value (2035) | USD 229.6 Mn |
| CAGR (2026–2035) | 14.4% |

Latin America Smart Inhalers Market
Brazil's health technology agency CONITEC reviewed its national COPD clinical protocol in 2025, one sign that respiratory care standards across the region are being rewritten. Latin America accounts for 5.0% of 2025 revenue (USD 62.3 Mn), with Brazil and Mexico the largest markets, both carrying a heavy asthma burden documented by the Global Asthma Network. Private hospital groups and insurers run most connected inhaler pilots, since public systems fund the medicine but not the sensor. That funding gap is the region's main constraint. In numbers, Latin America's USD 62.3 Mn equals roughly one-sixth of the U.S. market alone.
The Middle East Smart Inhalers Market
Saudi Arabia's SEHA Virtual Hospital, run by the Ministry of Health, connects about 130 hospitals, the kind of infrastructure that remote inhaler monitoring plugs into. The Middle East holds 4.0% of 2025 revenue (USD 49.9 Mn), concentrated in Saudi Arabia, the UAE and Israel, where digital health budgets sit inside national transformation programs. Outside those markets, few payers reimburse monitoring, which keeps device volumes low. Pharma companies are building the patient base first: Cipla expanded its Breathefree respiratory initiative across the UAE in October 2025.
Africa Smart Inhalers Market
The Global Asthma Report profiles South Africa as a country where many patients still lack regular access to controller inhalers, and that sets the order of priorities across the continent. Africa holds 3.0% of 2025 revenue (USD 40.0 Mn), led by South Africa and Egypt, where private hospital networks and medical schemes account for most connected device use. Smartphone coverage among older COPD patients and the cost of a sensor remain the main barriers. Structurally, African demand is a pharmacy-and-cellular market rather than a clinic-and-Bluetooth one, because patients collect inhalers at pharmacies and many lack a paired phone.


Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
Policy and Government Support Shaping the Smart Inhalers Market
Reimbursement/funding initiative — CMS's 2026 Physician Fee Schedule added CPT 99445 (2 to 15 days of device data) and CPT 99470 (the first 10 minutes of monitoring management), so U.S. practices can bill connected inhaler programs for patients who don't sync every day. (CMS CY2026 Medicare Physician Fee Schedule)
Regulatory-approval program — The FDA's 510(k) pathway clears add-on sensors inhaler by inhaler; Aptar Digital Health's connected MDI add-on was cleared as a Class II device in October 2025. (FDA 510(k) premarket notification)
Environmental and public health policy — The EU F-gas Regulation brings inhaler propellants into the hydrofluorocarbon phase-down, pushing AstraZeneca, GSK and Chiesi to reformulate devices and giving manufacturers a natural point to embed sensors. (EU F-gas Regulation (EU) 2024/573)
Digitization policy — South Korea's Digital Medical Products Act created a dedicated regulatory track for connected medical devices from January 2025, while NICE's early-use assessment in England set out evidence requirements for digital asthma self-management tools. (South Korea Digital Medical Products Act)
Recent Developments in the Smart Inhalers Market
Recent activity clusters around sensor clearances, low-carbon inhaler redesigns and specialist-practice monitoring partnerships rather than large acquisitions.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Oct 2025 | AptarGroup (Aptar Digital Health) | Regulatory | Received FDA 510(k) clearance for its Sense device, a Class II connected add-on device for metered dose inhalers. [source] | Adds a second large component supplier to the U.S. add-on sensor segment. |
| Oct 2025 | GSK | Other | Reported positive pivotal Phase III data for a next-generation low-carbon Ventolin MDI using HFA-152a propellant. [source] | Moves the most-prescribed rescue inhaler toward a redesign that can carry built-in sensing. |
| Mar 2026 | Chiesi Farmaceutici | Partnership | Expanded its partnership with Bespak to manufacture Carbon Minimal Inhalers at Holmes Chapel, UK. [source] | Secures low-GWP pMDI capacity in Europe ahead of the F-gas phase-down. |
| Apr 2026 | AstraZeneca | Regulatory | Won FDA approval of Breztri Aerosphere for the maintenance treatment of asthma in patients aged 12 and older. [source] | Widens the asthma population using an inhaler that Hailie sensors already support. |
| Jul 2026 | ResMed (Propeller Health) | M&A | Agreed to sell its MatrixCare software business to Frazier Healthcare Partners for US$490 Mn to focus on sleep and connected care. [source] | Concentrates ResMed's investment on respiratory and sleep platforms, including Propeller. |
| Oct 2026 | Adherium | Partnership | Partnered with Florida Lung, Asthma & Sleep Specialists (FLASS) to expand Hailie remote monitoring into Central Florida. [source] | Extends billable specialist-practice monitoring under the 2026 CMS codes. |
Research Methodology
Overall approach
Vectomat Insights sized the Smart Inhalers market from two directions. Bottom-up, analysts built unit and price estimates for add-on, integrated and disposable devices by application and channel; top-down, they reconciled those estimates with reported respiratory device revenue and with the asthma and COPD patient pools published by the WHO, GINA and GOLD. The two views were triangulated to a 2025 base of USD 1,246.7 Mn and projected to 2035 at a 12.18% CAGR.
Primary research
Analysts held structured interviews with pulmonologists, allergy practice managers, hospital and retail pharmacists, device engineers at inhaler component suppliers, and remote monitoring program managers in the U.S., Europe and Asia Pacific. Interviews tested sensor pricing, device replacement cycles, monitoring enrollment rates and the effect of the 2026 CMS billing codes on practice economics.
Secondary research
Secondary sources include FDA 510(k) decision records for connected inhaler sensors, CMS Physician Fee Schedule rules, EU F-gas and MDR texts, NICE guidance, company press releases and investor reports from Adherium, AptarGroup, AstraZeneca, GSK, Chiesi and Teva, and peer-reviewed studies on connected inhaler adherence.
Data validation
Segment and regional values were reconciled to the 2025 base-year total, country values were checked against their regional totals, and the resulting figures were cross-checked against reported company revenue and disclosed device activation counts before the forecast was finalized.
Market Coverage Definitions
How this report defines the scope of the Smart Inhalers Market: what each segment and sub-segment includes.
| Segment | Market Coverage Definition |
|---|---|
| By Product Type | Segments the market by the physical form of the smart inhaler device, covering add-on smart inhalers, integrated smart inhalers, and disposable smart inhalers. |
| By Application | Segments the market by the respiratory condition the device is used to manage, covering asthma, COPD, and other respiratory applications. |
| By Connectivity | Segments the market by the wireless technology used to transmit inhaler usage data, covering Bluetooth-enabled, cellular-enabled, and NFC-enabled devices. |
| By Distribution Channel | Segments the market by how patients obtain the device, covering hospital pharmacies, retail pharmacies, and online pharmacies. |
| By End User | Segments the market by where the device is primarily used, covering homecare and patient self-use, hospitals and clinics, and other end-use settings. |
By Product Type
| Sub-Segment | Market Coverage Definition |
|---|---|
| Add-On Smart Inhalers | Sensor devices that attach to an existing, otherwise conventional metered dose or dry powder inhaler, converting it into a connected device without changing the inhaler or drug formulation itself. The most common product type given their compatibility with inhalers already in wide clinical use. |
| Integrated Smart Inhalers | Inhalers manufactured with sensing and connectivity built directly into the device from the start, rather than added afterward. Typically developed and sold as a single combination product by a pharmaceutical or device manufacturer. |
| Disposable Smart Inhalers | Single-use connected inhalers, including disposable add-on sensors, designed for a defined period of use or a single inhaler canister before replacement, often positioned for lower upfront cost or over-the-counter distribution. |
By Application
| Sub-Segment | Market Coverage Definition |
|---|---|
| Asthma | Smart inhalers used to support adherence, technique, and symptom tracking for patients managing asthma, the application with the largest patient population and the most established remote monitoring programs. |
| COPD | Smart inhalers used to support chronic obstructive pulmonary disease management, where consistent maintenance therapy adherence is closely tied to reducing exacerbations and hospital readmissions. |
| Others | Additional respiratory and related conditions where connected inhaler devices are used, including off-label and emerging use cases beyond asthma and COPD. |
By Connectivity
| Sub-Segment | Market Coverage Definition |
|---|---|
| Bluetooth-Enabled | Devices that pair directly with a patient's smartphone over Bluetooth to transmit usage data to a companion mobile app, the dominant connectivity approach given its low cost and broad smartphone compatibility. |
| Cellular-Enabled | Devices that transmit usage data directly over a cellular network without requiring a paired smartphone, used where consistent connectivity independent of patient smartphone ownership or app engagement is a priority, including some remote patient monitoring programs. |
| NFC-Enabled | Devices that use near-field communication, requiring a patient to tap the device against a smartphone or reader to transfer stored usage data, a lower-power and lower-cost alternative to continuous wireless connectivity. |
By Distribution Channel
| Sub-Segment | Market Coverage Definition |
|---|---|
| Hospital Pharmacies | Smart inhalers dispensed through hospital pharmacy channels, typically tied to inpatient or post-discharge respiratory care programs and hospital-run remote monitoring initiatives. |
| Retail Pharmacies | Smart inhalers dispensed through community and chain retail pharmacies, the primary channel for prescription smart inhalers reaching outpatients. |
| Online Pharmacies | Smart inhalers and add-on sensors sold through online and direct-to-consumer channels, including over-the-counter add-on devices that do not require a prescription in some markets. |
By End User
| Sub-Segment | Market Coverage Definition |
|---|---|
| Homecare/Patients | Patients using smart inhalers in their own homes as part of daily disease self-management, the largest end-use setting given that most inhaled respiratory therapy is self-administered outside a clinical setting. |
| Hospitals & Clinics | Smart inhalers used within hospital and outpatient clinic settings, including structured adherence monitoring programs run by respiratory care teams and post-discharge follow-up programs. |
| Others | Additional end-use settings, including long-term care facilities and school or workplace health programs that support inhaler use outside the home or a formal clinical setting. |
Market Assessment Framework
The four-step framework used to size and validate the Smart Inhalers market.
- 1
Bottom-Up Approach
Market value is built up from individually identified smart inhaler products and add-on sensor devices, starting with cleared and commercially available products across add-on, integrated, and disposable device categories. Revenue for each product is estimated from device shipments, subscription or platform fees, and reimbursement revenue where applicable, then aggregated upward to the product type, application, and total market level.
- 2
Volume-Based Assessment
Device shipment and activation volumes are estimated separately for prescription-based products distributed through hospital and retail pharmacies and for direct-to-consumer and over-the-counter add-on sensors sold through online channels. Eligible patient population, prescribing and adoption rate, and device replacement cycle are modeled by product type and application rather than applying a single volume assumption across the market.
- 3
Price & Revenue Benchmarking
Device pricing, subscription fees, and per-patient remote monitoring reimbursement rates are benchmarked against publicly disclosed pricing for comparable connected respiratory devices, adjusted for regional reimbursement differences. Benchmarking distinguishes between one-time device purchase revenue and recurring remote patient monitoring subscription or billing revenue, which follow different growth trajectories.
- 4
Market Validation & Triangulation
Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported device shipment and activation figures, regulatory clearance disclosures, and reimbursement policy changes affecting remote patient monitoring billing. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.
Specialized Analyst Insights
The smart inhalers market has quietly shifted from a hardware story to a reimbursement story. The underlying sensor technology, detecting when an inhaler is used and how well a patient's technique matches the correct pattern, has been technically achievable for years. What has changed more recently is the payment model: new US billing codes that lower the amount of patient usage data required each month to bill for remote patient monitoring have made connected inhaler programs commercially viable at a scale that was difficult to reach under earlier, stricter reimbursement thresholds.
Propellant regulation is shaping smart inhaler strategy in a way that is easy to overlook. Most smart inhalers in the market today are add-on sensors designed to work with conventional metered dose inhalers, which still rely on hydrofluorocarbon propellants. Regulatory divergence between the United States, where regulators have renewed propellant allowances through 2030 without mandating a near-term switch, and Europe, where the transition toward lower global-warming-potential propellants is moving somewhat faster, means device manufacturers need their sensors to remain compatible with inhaler hardware that itself may change on different timelines across regions.
Regulatory bodies evaluating digital adherence tools have increasingly adopted a conditional, evidence-generation approach rather than an outright yes-or-no decision. The UK's National Institute for Health and Care Excellence recommending a slate of digital asthma management platforms for use within the NHS during a defined evidence-generation period, rather than issuing a final recommendation immediately, reflects a broader pattern across health systems: allow real-world use to generate the long-term outcomes data that a single clinical trial submission often cannot provide, then revisit the decision once that data exists.
Consolidation in this market has looked different from more capital-intensive drug categories. Rather than large acquisitions, the more common pattern has been strategic partnerships between device makers and pharmaceutical companies, and between device makers and specialty physician networks that provide access to insurance-verified patient populations. That reflects a category where the technology itself is relatively mature and inexpensive to produce, and where the harder problem, getting a connected device into a patient's hands and getting the resulting data paid for, is solved more through distribution and billing relationships than through owning more technology.
Regional Regulations
Regulatory authorities and requirements across 9 jurisdictions
| Region | Key Regulatory Authorities / Frameworks | Government Regulations and Regulatory Considerations |
|---|---|---|
| North AmericaU.S. | U.S. FDA, EPA | Connected inhaler add-on sensors are generally regulated by the FDA as Class II medical devices, requiring 510(k) clearance demonstrating substantial equivalence to an existing cleared device before marketing. Since most smart inhalers pair with conventional metered dose inhalers, the category is also shaped by EPA rules governing the hydrofluorocarbon propellants those inhalers use, with EPA renewing propellant allowances through 2030 rather than mandating a near-term reformulation. |
| Europe | European Commission, Notified Bodies | Connected inhaler sensor devices generally require CE marking under the EU Medical Device Regulation when sold as a standalone device, while the inhaler and drug formulation itself is regulated separately as a medicinal product. Europe's approach to propellant reformulation has also moved somewhat faster than other regions, aligned with broader EU climate policy on fluorinated gases. |
| Asia PacificJapan | PMDA, MHLW | Connected inhaler sensors are regulated as medical devices under Japan's Pharmaceuticals and Medical Devices Act, with classification depending on the device's functional risk. Japan has not set a low global-warming-potential propellant transition timeline comparable to the EU's, leaving most approved inhalers on existing propellant formulations for now. |
| Asia PacificChina | NMPA | Connected inhaler devices are regulated as medical devices under China's device classification catalogue, administered by the NMPA, with digital health and software functionality generally requiring separate software registration alongside the physical device. |
| Asia PacificIndia | CDSCO | Connected inhaler devices fall under India's Medical Device Rules, with digital health and software-as-a-medical-device oversight still maturing relative to the regulatory framework for the underlying inhaler drug products, an area the Central Drugs Standard Control Organisation has continued to expand. |
| Asia PacificSouth Korea | MFDS | Connected inhaler devices are regulated under South Korea's Medical Device Act, with digital health software components generally reviewed through a separate track from the physical device itself. |
| Latin AmericaBrazil | ANVISA | Connected inhaler sensors are regulated as medical devices by ANVISA, with import and local registration requirements applying to internationally developed devices entering the Brazilian market, where patient access has generally followed availability in the US and Europe. |
| Middle East | National health product regulatory authorities, GCC frameworks | Connected respiratory devices are generally reviewed under national drug and device frameworks, with growing Gulf Cooperation Council interest in digital health and remote patient monitoring programs as part of broader chronic disease management strategy. |
| Global / International | ISO, WHO | International standards support device quality and software interoperability, including general medical device and software quality management standards. The World Health Organization's guidance on noncommunicable disease management has increasingly referenced digital adherence tools, including connected inhalers, as a way to improve asthma and COPD outcomes in resource-limited settings. |
Strategic Activities
5 strategic developments shaping the Smart Inhalers Market
| Date | Company / Companies | Development Type | Development and Impact on Market |
|---|---|---|---|
| Aug 2025 | U.S. EPA | Regulatory Change | The EPA finalized a rule renewing priority access to hydrofluorocarbon propellant allowances for metered dose inhalers through 2030, finding that no safe or technically achievable substitute propellant has yet been approved by the FDA for use in an MDI. The decision gives manufacturers of both conventional and sensor-equipped add-on inhalers continued regulatory certainty over their existing hardware for the rest of the decade, while leaving the longer-term propellant transition unresolved. [source] |
| Oct 2025 | Aptar Digital Health | Regulatory Approval | Aptar Digital Health received FDA 510(k) clearance for HeroTracker Sense, a Bluetooth-enabled sensor that attaches to pressurized metered dose inhalers to track usage, provide adherence reminders, and give patients feedback on inhaler technique through a companion mobile app. The clearance added another cleared add-on sensor to a product category increasingly competing on data quality and app experience rather than core sensing technology. [source] |
| Jan 2026 | NICE | Regulatory Guidance | The UK's National Institute for Health and Care Excellence issued draft guidance recommending eight digital asthma management platforms, including connected inhaler monitoring systems, for conditional use within the NHS during a three-year evidence-generation period. Rather than a final yes-or-no decision, NICE will review additional real-world outcomes data gathered during that period before deciding on routine NHS adoption. [source] |
| Mar 2026 | Adherium | Reimbursement Update | Adherium reported that new US CPT billing codes effective January 2026, which lower the amount of patient usage data required each month to bill for remote patient monitoring, helped drive a 51 percent quarter-over-quarter increase in its Hailie Smartinhaler remote monitoring revenue, alongside a 43 percent rise in cumulative device shipments. The company said it had access to roughly 48,000 insurance-verified asthma patients with compatible inhalers through its physician network partnerships. [source] |
| Apr 2026 | Adherium, AstraZeneca | Capital Raise | Adherium completed a capital raise of roughly $6.78 million, reporting that the company was now debt free, while also disclosing an existing partnership with AstraZeneca under which a further milestone payment of approximately $264,000 was expected in July 2026. The combination of fresh capital and an ongoing pharmaceutical company partnership reflected the funding path smaller connected device companies have increasingly relied on to reach commercial scale. [source] |
Related Analysis
Blog · Medical Devices & EquipmentThe Smart Inhaler Story Isn't About the Sensor Anymore, It's About Who Pays for the Data
A new FDA clearance, a cautious NICE recommendation, and a small Australian company's shipment numbers all point to the same conclusion: the technology behind connected inhalers has been ready for years. What changed recently is who gets paid, and how much usage data it takes to bill for it.
Read the article →Table of Contents: Smart Inhalers Market Report
14 chapters · 118 tables & 86 figures. Expand a chapter to see its sub-sections.
Introduction
- Market Definition and Scope
- Research Objectives
Research Methodology
- Primary Research
- Secondary Research
- Top-Down and Bottom-Up Triangulation
- Data Validation
Executive Summary
- Key Findings, 2025
- Market Snapshot, 2026–2035
Market Dynamics
- Growth Drivers
- Restraints
- Opportunities
- Challenges
- AI's Impact on the Smart Inhalers Market
Smart Inhalers Market — By Product Type
- Add-On Smart Inhalers
- Integrated Smart Inhalers
- Disposable Smart Inhalers
- Product Type Revenue and Share Analysis, 2023–2025
- Production & Volume Analysis, 2025 (units shipped)
Smart Inhalers Market — By Application
- Asthma
- COPD
- Others (Cystic fibrosis, allergic rhinitis, and other respiratory conditions)
- Application Revenue and Share Analysis, 2023–2025
Smart Inhalers Market — By Connectivity
- Bluetooth-Enabled
- Cellular-Enabled
- NFC-Enabled
- Connectivity Revenue and Share Analysis, 2023–2025
Smart Inhalers Market — By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Distribution Channel Revenue and Share Analysis, 2023–2025
Smart Inhalers Market — By End User
- Homecare/Patients
- Hospitals & Clinics
- Others (Long-term care facilities, ambulatory surgical centers, and pharmacies)
- End User Revenue and Share Analysis, 2023–2025
Regional Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Competitive Landscape
- Market Share Analysis, 2025
- Competitive Positioning Matrix
- Smart Inhalers Market: Value Chain Overview
Company Profiles
- Adherium
- ResMed (Propeller Health)
- AptarGroup (Aptar Digital Health)
- Teva Pharmaceutical Industries
- AstraZeneca
- GSK
- Chiesi Farmaceutici
- Boehringer Ingelheim
- Cipla
- Lupin
- Kindeva Drug Delivery
- Bespak
Recent Developments
- Regulatory Clearances and Approvals
Appendix
- Sources
- Abbreviations and Glossary
List of Tables (selected)
- Smart Inhalers Market Size, 2023–2035 (USD Million)
- Smart Inhalers Market Size, By Product Type, 2023–2025 (USD Million)
- Smart Inhalers Market Size, By Application, 2023–2025 (USD Million)
- Smart Inhalers Market Size, By Connectivity, 2023–2025 (USD Million)
- Smart Inhalers Market Size, By Distribution Channel, 2023–2025 (USD Million)
- Smart Inhalers Market Size, By End User, 2023–2025 (USD Million)
- Smart Inhalers Market Production & Volume, By Product Type, 2025 (units shipped)
- Smart Inhalers Market Share, By Region, 2025 (%)
- North America Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- Europe Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- Asia Pacific Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- Latin America Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- The Middle East Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- Africa Smart Inhalers Market, By Country, 2025–2035 (USD Million)
- U.S. Smart Inhalers Market Snapshot, 2025–2035
- Germany Smart Inhalers Market Snapshot, 2025–2035
- South Korea Smart Inhalers Market Snapshot, 2025–2035
- Key Companies: Primary Focus, Strategy and Recent Actions
- Recent Developments in the Smart Inhalers Market, 2025–2026
List of Figures (selected)
- Smart Inhalers Market Size, 2025–2035 (USD Million)
- Smart Inhalers Market: Drivers, Restraints, Opportunities & Challenges
- Smart Inhalers Market Share by Region, 2025
- Smart Inhalers Market — Segmentation Overview
- Smart Inhalers Market Share, By Product Type, 2025 (%)
- Smart Inhalers Market Share, By End User, 2025 (%)
- Smart Inhalers Market — Product Type Mix by Region
- Smart Inhalers Market — Competitive Landscape
- Smart Inhalers Market — At a Glance
- U.S. Smart Inhalers Market Size, USD Million
- Germany Smart Inhalers Market Size, USD Million
- South Korea Smart Inhalers Market Size, USD Million
You May Also Be Interested In
Remote Patient Monitoring Market
Smart inhaler data feed the same billed remote monitoring programs and platforms.
Respiratory Inhalers Market
Shares pharma brand owners and the low-carbon propellant transition.
Digital Therapeutics Market
Overlapping buyers among payers and health systems funding digital adherence tools.
Nebulizers Market
Same asthma and COPD patient base and homecare distribution channels.
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
What does the VMI Smart Inhalers report include?
The report sizes the Global Smart Inhalers market for 2023–2025 and forecasts it to 2035 by product type, application, connectivity, distribution channel and end user, across six regions and 35+ countries. It includes a production and volume analysis, drivers, restraints, opportunities and challenges, a value chain review, recent developments and profiles of 12 companies with their recent strategic moves, according to Vectomat Insights.
What is the Smart Inhalers market size and forecast?
The market was valued at USD 1,246.7 Mn in 2025 and is projected to reach USD 3,934.7 Mn by 2035, growing at a 12.18% CAGR during 2026–2035. North America holds 38.0% of 2025 revenue, add-on sensors account for 54.0% of product revenue, and asthma is the largest application at 56.0%, while integrated devices grow fastest at 16.17% a year, according to Vectomat Insights.
How is the Smart Inhalers market segmented in this report?
The report uses five dimensions: product type (add-on, integrated and disposable smart inhalers), application (asthma, COPD and other respiratory conditions), connectivity (Bluetooth, cellular and NFC), distribution channel (hospital, retail and online pharmacies) and end user (homecare/patients, hospitals and clinics, and other settings). Each dimension has revenue tables for 2023–2025 and forecasts to 2035, plus share charts for product type and end user, according to Vectomat Insights.
Which countries are covered in this report?
The report covers 35+ countries across six regions, with Africa and the Middle East analysed as two separate regions. Featured markets include the U.S., Canada and Mexico; Germany, France and the U.K.; China, Japan, India and South Korea; Brazil; the GCC states and Israel; and South Africa and Egypt. Snapshot forecasts are provided for the U.S., Germany and South Korea, according to Vectomat Insights.
What customization options are available?
Buyers can customize up to 10% of the report scope at no extra cost when they order. Common requests include additional country splits, extra company profiles, a separate cut for a specific inhaler brand family, or deeper analysis of remote monitoring reimbursement in a chosen market. Larger custom studies are scoped and quoted separately by the analyst team, according to Vectomat Insights.
How can I access or purchase the Smart Inhalers report?
The report is delivered as a PDF by email and through an online download portal. You can request a free sample from the report page, buy the full report online, or contact sales@vectomatinsights.com for licensing and enterprise access. A sample shows the table of contents, selected tables and the methodology before purchase, so teams can check fit with their needs, according to Vectomat Insights.
What research methodology does VMI use for this report?
Analysts combined a bottom-up model of device units and prices with a top-down view built from reported company revenue and asthma and COPD patient populations, then triangulated the two. Interviews with pulmonologists, pharmacists, device engineers and monitoring program managers tested pricing and adoption assumptions, and segment, regional and country values were reconciled to the base-year total, according to Vectomat Insights.
Access the Complete Smart Inhalers Market Report
300+ pages | 118 tables & 86 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI Smart Inhalers Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.
About this report
Get a free sample of this report
Smart Inhalers Market